Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACDC: Dendritic Cell Vaccine in Resected Melanoma
NCT02718391Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Aug 2015
- Primary completion
- Nov 2019
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of autologous dendritic cell vaccine in melanoma, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Aug 2015; status: terminated.
02
Drugs
autologous dendritic cell vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02718391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02718391.